Dr. Harry Menon, DO, MPH
Hematology & Oncology (Hematology & Oncology Physician)
Who else practices at this address →
Washoe County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Lake Erie Col of Osteopathic Medicine, Bradenton (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 297
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: Lake Erie Col of Osteopathic Medicine, Bradenton
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NV license DO2896 -
Internal Medicine Physician
NV license DO2896 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Renown Regional Medical Center Reno, NV
- Renown South Meadows Medical Center Reno, NV
- Carson Valley Health Gardnerville, NV
- Banner Churchill Community Hospital Fallon, NV
- Banner Lassen Medical Center Susanville, CA
Medical groups
- Community Care Services LLC (641 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 297
- Services billed
- 876
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 363 | 118 |
| Established patient office or other outpatient visit, 20-29 minutes | 98 | 68 |
| New patient office or other outpatient visit, 60-74 minutes | 54 | 54 |
| Established patient office or other outpatient visit, 40-54 minutes | 24 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Reno, NV | 163 |
| Prochlorperazine Maleate Other prescribers in Reno, NV | 133 |
| Prednisone Other prescribers in Reno, NV | 106 |
| Acyclovir Other prescribers in Reno, NV | 105 |
| Dexamethasone Other prescribers in Reno, NV | 71 |
| Revlimid (lenalidomide) | 70 |
| Eliquis (apixaban) Other prescribers in Reno, NV | 51 |
| Xarelto (rivaroxaban) Other prescribers in Reno, NV | 39 |
| Olanzapine Other prescribers in Reno, NV | 33 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Reno, NV | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 32 companies reported 94 payments worth $48,855 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $15,991 |
|---|---|
| Genzyme Corporation | $15,312 |
| Genentech USA, Inc. | $11,141 |
| Pfizer Inc. | $2,102 |
| Incyte Corporation | $2,018 |
| Daiichi Sankyo Inc. | $743 |
| Deciphera Pharmaceuticals Inc. | $184 |
| Janssen Biotech, Inc. | $167 |
| Compensation for services other than consulting (speaking, faculty) | $21,969 |
|---|---|
| Consulting Fee | $21,529 |
| Food and Beverage | $3,166 |
| Travel and Lodging | $2,190 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $9,309 |
| Genentech USA, Inc. Aug 20, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $5,539 |
| Genzyme Corporation Nov 1, 2025 | Consulting Fee | $5,430 |
| AstraZeneca Pharmaceuticals LP Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $5,360 |
| AstraZeneca Pharmaceuticals LP May 16, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $5,360 |
| Genentech USA, Inc. Aug 21, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $4,209 |
| Pfizer Inc. Nov 12, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| Incyte Corporation Jun 25, 2025 | Consulting Fee | $1,925 |
| AstraZeneca Pharmaceuticals LP May 12, 2025 | Consulting Fee IMFINZI · Oncology | $1,675 |
| AstraZeneca Pharmaceuticals LP Aug 19, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,340 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) IMFINZI · Oncology Company’s descriptionSpeaker Fee | $300 |
| AstraZeneca Pharmaceuticals LP Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) IMFINZI · Oncology Company’s descriptionSpeaker Fee | $300 |
| Pfizer Inc. Nov 12, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| Genzyme Corporation Nov 1, 2025 | Consulting Fee | $5,430 |
| Daiichi Sankyo Inc. Sep 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Genentech USA, Inc. Aug 21, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $4,209 |
| Genentech USA, Inc. Aug 20, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $5,539 |
| Genentech USA, Inc. Aug 20, 2025 | Travel and Lodging Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind | $474 |
| Genentech USA, Inc. Aug 20, 2025 | Travel and Lodging Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind | $390 |
| Genentech USA, Inc. Aug 20, 2025 | Travel and Lodging Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind | $34.61 |
| AstraZeneca Pharmaceuticals LP Aug 19, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,340 |
| AstraZeneca Pharmaceuticals LP Jul 2, 2025 | Travel and Lodging travel to Granite Bay, CA | $178 |
| AstraZeneca Pharmaceuticals LP Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $5,360 |
| Incyte Corporation Jun 25, 2025 | Consulting Fee | $1,925 |
| AstraZeneca Pharmaceuticals LP May 16, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $5,360 |
| AstraZeneca Pharmaceuticals LP May 14, 2025 | Travel and Lodging travel to Anchorage, AK · in-kind Company’s descriptionSpeaker Expenses | $1,043 |
| AstraZeneca Pharmaceuticals LP May 12, 2025 | Consulting Fee IMFINZI · Oncology | $1,675 |
| Genzyme Corporation Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $9,309 |
| Genzyme Corporation Jan 29, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Las Vegas, NV | $70.74 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $110,893 in research payments for these studies, mostly to the institutions running them.
- An interventional openlabel phase 1B2 study to evaluate safety pharmacokinetics and preliminary efficacy of PF08634404 as monotherapy and combination therapy in adult participants with unresectable locally advanced or…
Pfizer Inc. - A phase 2B3 randomized doubleblind study to investigate the efficacy safety and tolerability of ponsegromab PF06946860 compared with placebo both with background firstline chemotherapy in adult participants with cache…
Pfizer Inc. - A randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer
AstraZeneca Pharmaceuticals LP - A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.